◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Appili Therapeutics Inc.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Total Revenue 103,935 0.00 -12,606 108,359 4,690 --
Operating Revenue 103,935 0.00 -12,606 108,359 4,690 --
Selling General And Administration 564,228 642,469 991,764 443,261 653,638 --
General And Administrative Expense 564,228 642,469 991,764 443,261 653,638 --
Research And Development 838,352 960,973 1.5M 1.7M 2.1M --
Other Operating Expenses -223,069 -550,886 -2.5M -2.6M -2.4M --
Operating Expense 1.2M 1.1M 49,197 -388,713 333,703 --
Operating Income -1.1M -1.1M -61,803 497,072 -329,013 --
EBIT -1.1M -732,656 925,237 -12,280 -212,045 --
Interest Expense -- 486,066 669,552 522,022 530,289 1.2M
Interest Expense Non Operating -- 486,066 669,552 522,022 530,289 1.2M
Interest Income 218,439 -- 0.00 36.00 0.00 0.00
Interest Income Non Operating 218,439 -- 0.00 36.00 0.00 0.00
Net Interest Income 218,439 -486,066 -1.2M -521,986 -530,289 --
Other Income Expense -96,962 319,900 1.5M -509,388 116,968 --
Gain On Sale Of Security -96,962 319,900 119,977 -509,388 116,968 --
Pretax Income -954,099 -1.2M 255,685 -534,302 -742,334 --
Tax Provision 34,966 30,859 27,635 -9,965 1,160 --
Tax Effect Of Unusual Items -14,544 47,985 12,967 -9,500 17,545 --
Net Income From Continuing And Discontinued Operation -989,065 -1.2M 228,050 -524,337 -743,494 --
Net Income From Continuing Operation Net Minority Interest -989,065 -1.2M 228,050 -524,337 -743,494 --
Net Income Including Noncontrolling Interests -989,065 -1.2M 228,050 -524,337 -743,494 --
Net Income Common Stockholders -989,065 -1.2M 228,050 -524,337 -743,494 --
Net Income -989,065 -1.2M 228,050 -524,337 -743,494 --
EBITDA -1.1M -729,040 928,445 -8,205 -209,233 --
Normalized EBITDA -975,369 -1.0M 808,468 501,183 -326,201 --
Reconciled Depreciation 3,245 3,616 3,208 4,075 2,812 --
Basic EPS -0.01 -0.01 -- 0.00 -0.01 -0.01
Diluted EPS -0.01 -0.01 -- 0.00 -0.01 -0.01
Basic Average Shares 121.3M 121.3M -- 121.3M 121.3M 121.3M
Diluted Average Shares 121.3M 121.3M -- 121.3M 121.3M 121.3M
Total Unusual Items -96,962 319,900 119,977 -509,388 116,968 --
Total Unusual Items Excluding Goodwill -96,962 319,900 119,977 -509,388 116,968 --
Tax Rate For Calcs 0.15 0.15 0.11 0.02 0.15 --
Normalized Income -906,647 -1.5M 121,040 -24,449 -842,917 --
Diluted NI Availto Com Stockholders -989,065 -1.2M 228,050 -524,337 -743,494 --
Net Income Continuous Operations -989,065 -1.2M 228,050 -524,337 -743,494 --
Net Non Operating Interest Income Expense 218,439 -486,066 -1.2M -521,986 -530,289 --
Other Gand A 564,228 642,469 991,764 443,261 653,638 --
Total Expenses 1.2M 1.1M 49,197 -388,713 333,703 --
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Cash And Cash Equivalents 348,679 1.1M 1.2M 186,166 665,219 --
Cash Cash Equivalents And Short Term Investments 348,679 1.1M 1.2M 186,166 665,219 --
Cash Financial 348,679 1.1M 1.2M 186,166 665,219 --
Receivables 201,593 515,288 1.7M 1.8M 750,675 --
Prepaid Assets 192,004 244,378 114,514 125,772 112,690 --
Current Assets 742,276 1.9M 3.0M 2.1M 1.5M --
Net PPE 12,182 15,427 19,043 22,250 25,623 --
Total Non Current Assets 12,182 15,427 19,043 22,250 25,623 --
Total Assets 754,458 1.9M 3.0M 2.1M 1.6M --
Current Debt 11.6M 11.6M 11.6M 10.5M 9.6M --
Current Debt And Capital Lease Obligation 11.6M 11.6M 11.6M 10.5M 9.6M --
Accounts Payable 4.1M 4.2M 4.1M 4.4M 4.2M --
Payables 4.1M 4.2M 4.1M 4.4M 4.2M --
Payables And Accrued Expenses 4.1M 4.2M 4.1M 4.4M 4.2M --
Current Liabilities 15.8M 15.8M 15.7M 14.9M 13.9M --
Long Term Debt 609,000 703,200 736,100 811,400 814,100 --
Long Term Debt And Capital Lease Obligation 609,000 703,200 736,100 811,400 814,100 --
Total Non Current Liabilities Net Minority Interest 609,000 703,200 736,100 811,400 814,100 --
Total Liabilities Net Minority Interest 16.4M 16.5M 16.4M 15.7M 14.7M --
Common Stock 42.3M 42.3M 42.3M 42.3M 42.3M --
Capital Stock 42.3M 42.3M 42.3M 42.3M 42.3M --
Additional Paid In Capital 15.5M 14.8M 14.8M 14.8M 13.1M --
Retained Earnings -74.0M -73.0M -71.7M -71.9M -71.4M --
Common Stock Equity -15.6M -14.6M -13.4M -13.6M -13.1M --
Stockholders Equity -15.6M -14.6M -13.4M -13.6M -13.1M --
Total Equity Gross Minority Interest -15.6M -14.6M -13.4M -13.6M -13.1M --
Total Capitalization -15.0M -13.9M -12.7M -12.8M -12.3M --
Net Tangible Assets -15.6M -14.6M -13.4M -13.6M -13.1M --
Tangible Book Value -15.6M -14.6M -13.4M -13.6M -13.1M --
Working Capital -15.0M -13.9M -12.7M -12.8M -12.3M --
Invested Capital -3.4M -2.3M -1.1M -2.3M -2.7M --
Total Debt 12.2M 12.4M 12.3M 11.3M 10.4M --
Net Debt 11.9M 11.2M 11.1M 11.1M 9.8M --
Share Issued 121.3M 121.3M 121.3M 121.3M 121.3M --
Ordinary Shares Number 121.3M 121.3M 121.3M 121.3M 121.3M --
Other Equity Interest 564,434 1.2M 1.2M 1.2M 2.8M --
Other Receivables 149,706 425,314 1.6M 1.7M 664,169 --
Taxes Receivable 51,887 89,974 71,540 90,772 86,506 --
Total Tax Payable 15,198 15,602 29,471 1,846 42,496 --
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Operating Cash Flow -759,376 -6,356 1.0M -442,371 409,027 --
Cash Flow From Continuing Operating Activities -759,376 -6,356 1.0M -442,371 409,027 --
Depreciation And Amortization 3,245 3,616 3,208 4,075 2,812 --
Depreciation Amortization Depletion 3,245 3,616 3,208 4,075 2,812 --
Stock Based Compensation 11,576 18,096 10,688 12,834 14,266 --
Change In Working Capital 326,986 1.1M -200,831 -833,191 722,091 --
Changes In Account Receivables 303,695 1.2M 91,903 -1.0M 1.0M --
Change In Receivables 313,695 1.2M 88,603 -1.0M 1.0M --
Change In Payables And Accrued Expense -39,083 41,612 -300,692 188,692 -319,581 --
Change In Payable -- -- -- -- -- 625,008
Other Non Cash Items 92,806 473,570 1.2M 507,842 509,249 --
Capital Expenditure -- -- -- -702.00 -- --
Purchase Of PPE 0.00 0.00 0.00 -702.00 -1,658 --
Net PPE Purchase And Sale 0.00 0.00 0.00 -702.00 -1,658 --
Investing Cash Flow 0.00 0.00 0.00 -702.00 -1,658 --
Cash Flow From Continuing Investing Activities 0.00 0.00 0.00 -702.00 -1,658 --
Issuance Of Debt 0.00 0.00 0.00 0.00 0.00 --
Repayment Of Debt -30,091 -29,298 -44,856 -27,556 -26,645 --
Net Issuance Payments Of Debt -30,091 -29,298 -44,856 -27,556 -26,645 --
Financing Cash Flow -77,415 -42,283 -61,209 -40,562 -42,973 --
Cash Flow From Continuing Financing Activities -77,415 -42,283 -61,209 -40,562 -42,973 --
Effect Of Exchange Rate Changes 60,421 -54,556 69,052 4,582 -442.00 --
Changes In Cash -836,791 -48,639 973,026 -483,635 364,396 --
Beginning Cash Position 1.1M 1.2M 186,166 665,219 301,265 --
End Cash Position 348,679 1.1M 1.2M 186,166 665,219 --
Free Cash Flow -759,376 -6,356 1.0M -443,073 407,369 --
Interest Paid Supplemental Data -- -- -- -1.0M 1.0M 18,814
Cash Dividends Paid 0.00 0.00 0.00 0.00 0.00 --
Change In Account Payable -- -- -- -- -- 625,008
Change In Prepaid Assets 52,374 -129,864 11,258 -13,082 4,010 --
Depreciation 3,245 3,616 3,208 4,075 2,812 --
Interest Paid Cff -47,324 -12,985 -16,353 -13,006 -16,328 --
Long Term Debt Issuance 0.00 0.00 0.00 0.00 0.00 --
Long Term Debt Payments -30,091 -29,298 -44,856 -27,556 -26,645 --
Net Foreign Currency Exchange Gain Loss -204,923 -319,390 -177,013 390,406 -95,897 --
Net Income From Continuing Operations -989,066 -1.2M 228,050 -524,337 -743,494 --
Net Long Term Debt Issuance -30,091 -29,298 -44,856 -27,556 -26,645 --
Operating Gains Losses -204,923 -319,390 -177,013 390,406 -95,897 --
NEWS
Loading news...
TRENDING
Loading...